^
    13h
    DSP-5336-101: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (clinicaltrials.gov)
    P1/2, N=606, Recruiting, Sumitomo Pharma America, Inc. | N=362 --> 606
    Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • enzomenib (DSP-5336)
    14h
    AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • HEOR
    |
    Calquence (acalabrutinib)
    14h
    Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    15h
    Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=51, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • etoposide IV
    21h
    NCI-2019-03057: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Mar 2027
    Trial completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation • IDH1 R132 • IDH2 R172
    |
    Lynparza (olaparib)
    22h
    TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients (clinicaltrials.gov)
    P3, N=180, Not yet recruiting, Shenzhen TargetRx Co., Ltd.
    New P3 trial
    |
    TGRX-678
    1d
    A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=20, Suspended, University of Michigan Rogel Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • cytarabine • fludarabine IV
    1d
    Phase IB/II of CPX-351 for Relapse Prevention in AML (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Georgetown University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1d
    US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (clinicaltrials.gov)
    P2, N=30, Completed, ExCellThera inc. | Active, not recruiting --> Completed
    Trial completion
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • fludarabine IV • Zemcelpro (dorocubicel)
    2d
    Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    sorafenib • bortezomib • decitabine
    2d
    CHIS: Clonal Hematopoiesis of Immunological Significance (clinicaltrials.gov)
    P=N/A, N=5000, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | N=1000 --> 5000 | Trial primary completion date: Sep 2045 --> Apr 2036
    Enrollment change • Trial primary completion date
    3d
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Completed, OncoVerity, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    azacitidine • cusatuzumab (ARGX-110)